Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
$33.77
$0.18(0.83%)
At close: 4:00 PM EST
$33.77
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$12.47 - $37.35
Previous CloseN/A
Volume1.13M
Average Volume (3M)8.69M
Market Cap
$39.42B
Enterprise Value$52.69B
Total Cash (Recent Filing)$3.56B
Total Debt (Recent Filing)$17.38B
Price to Earnings (P/E)27.7
Beta0.66
Next Earnings
May 13, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.96
Shares Outstanding1,164,638,700
10 Day Avg. Volume5,811,601
30 Day Avg. Volume8,694,604
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)4.53
Price to Sales (P/S)2.08
P/FCF Ratio31.24
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit5.89
Enterprise Value/Ebitda16.70
Forecast
1Y Price Target
$40.25Price Target Upside19.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)2.7
Revenue Forecast (FY)$16.69B
Bulls Say, Bears Say
Bulls Say
Clinical Profile And DosingDuvakitug's maintenance data showing sustained response with a monthly dosing schedule supports a competitive clinical profile that could improve patient convenience and adoption versus other TL1A therapies.
Commercial Outlook And ValuationAn analyst-led valuation increase after positive clinical data signals higher expected peak sales for duvakitug, implying stronger upside if clinical differentiation translates into market uptake.
R&D Funding And Balance SheetA Royalty Pharma partnership to fund the IL15 program provides non-dilutive capital that can accelerate development while limiting pressure on profitability and supporting balance sheet strength.
Bears Say
Development Timeline UncertaintyThe vitiligo program faces a long development timeline, creating uncertainty around when or if meaningful commercial benefits will be realized.
Market Entry And Competition RiskPivotal trials for duvakitug remain in progress and being behind a first mover could allow a competitor to establish market leadership, constraining Teva's commercial share.
Relative Valuation ConcernThe stock appears expensive versus specialty pharma peers, which could limit upside unless investor perceptions about growth prospects or risk profile change.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.46 and its highest was $37.34 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $39.42B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 28, 2026. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.641 by $0.319.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.55.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.96 in its last earnings report, beating expectations of $0.641. Following the earnings report the stock price went up 2.09%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.25 (19.19% Upside)
$40.25 (19.19% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 30.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.47%
12-Months-Change
Fundamentals
Return on Equity
21.37%
Trailing 12-Months
Asset Growth
3.61%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong progress on the company’s Pivot to Growth: double-digit growth in key innovative brands, improved gross margins, meaningful pipeline validation and clear deleveraging progress. These positives were tempered by dependency on a $500M milestone for headline Q4 growth, a flat generics business with regional softness, near-term one-time inventory/gross-to-net effects that complicate comparability, higher OpEx pressure and persistent clinical/catalyst risk. On balance the strong commercial momentum, improving margin profile and validated pipeline catalysts outweigh the transitory one-time effects and execution risks.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$40.25
▲(19.19% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.39% Insiders
4.80% Mutual Funds
17.54% Other Institutional Investors
72.55% Public Companies and Individual Investors